Your browser doesn't support javascript.
loading
Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
Fragoso, Yara Dadalti; Adoni, Tarso; Alves-Leon, Soniza Vieira; Apostolos-Pereira, Samira Luisa; Araujo, Yuna Ribeiro de; Becker, Jefferson; Brooks, Joseph Bruno Bidin; Correa, Eber Castro; Damasceno, Alfredo; Damasceno, Carlos Augusto de Albuquerque; Ferreira, Maria Lucia B; Gama, Paulo Diniz da; Gama, Rodrigo Assad Diniz da; Gomes, Sidney; Goncalves, Marcus Vinicius Magno; Grzesiuk, Anderson Kuntz; Machado, Suzana Costa Nunes; Matta, Andre Palma da Cunha; Mendes, Maria Fernanda; Ribeiro, Taysa Alexandrino Goncalves Jube; Rocha, Cristiane Franklin da; Ruocco, Heloisa Helena; Sato, Henry; Simm, Renata Faria; Tauil, Carlos Bernardo; Vasconcelos, Claudia Cristina Ferreira; Vieira, Vera Lucia Ferreira.
Afiliação
  • Fragoso YD; a Department of Neurology , Universidade Metropolitana de Santos , Santos , Brazil.
  • Adoni T; b Department of Neurology , Hospital Sirio Libanes , Sao Paulo , Brazil.
  • Alves-Leon SV; c Department of Neurology , Universidade Federal do Estado do Rio de Janeiro , Rio de Janeiro , Brazil.
  • Apostolos-Pereira SL; d Department of Neurology , Hospital das Clinicas da Universidade de Sao Paulo , Sao Paulo , Brazil.
  • Araujo YR; e Department of Neurology , Hospital de Base do Distrito Federal , Brasilia , Brazil.
  • Becker J; f Department of Neurology , Pontificia Universidade Catolica do Rio Grande do Sul , Porto Alegre , Brazil.
  • Brooks JBB; a Department of Neurology , Universidade Metropolitana de Santos , Santos , Brazil.
  • Correa EC; g Department of Neurology , CLINEN , Brasilia , Brazil.
  • Damasceno A; h Department of Neurology , Universidade Estadual de Campinas , Campinas , Brazil.
  • Damasceno CAA; i Department of Neurology , Universidade Federal de Juiz de Fora , Juiz de Fora , Brazil.
  • Ferreira MLB; j Department of Neurology , Hospital da Restauracao , Recife , Brazil.
  • Gama PDD; k Department of Neurology , Pontificia Universidade Catolica Sorocaba , Sorocaba , Brazil.
  • Gama RADD; k Department of Neurology , Pontificia Universidade Catolica Sorocaba , Sorocaba , Brazil.
  • Gomes S; l Department of Neurology , Hospital Beneficencia Portuguesa de Sao Paulo , São Paulo , Brazil.
  • Goncalves MVM; m Department of Neurology , Regional Hans Dieter Schimidt, Centro Hospitalar Unimed , Joinville , Brazil.
  • Grzesiuk AK; n Department of Neurology , CRIDAC , Cuiaba , Brazil.
  • Machado SCN; o Department of Neurology , Hospital de Caridade , Florianopolis , Brazil.
  • Matta APDC; p Department of Neurology , Universidade Federal Fluminense , Niteroi , Brazil.
  • Mendes MF; q Department of Neurology , Irmandade da Santa Casa de Misericordia de Sao Paulo , Sao Paulo , Brazil.
  • Ribeiro TAGJ; r Department of Neurology , Universidade Federal de Goias , Goiania , Brazil.
  • Rocha CFD; s Department of Neurology , Neurological Clinic Belo Horizonte , Belo Horizonte , Brazil.
  • Ruocco HH; t Department of Neurology , Universidade de Jundiai , Jundiai , Brazil.
  • Sato H; u Department of Neurology , Neurological Institute Curitiba , Curitiba , Brazil.
  • Simm RF; d Department of Neurology , Hospital das Clinicas da Universidade de Sao Paulo , Sao Paulo , Brazil.
  • Tauil CB; e Department of Neurology , Hospital de Base do Distrito Federal , Brasilia , Brazil.
  • Vasconcelos CCF; c Department of Neurology , Universidade Federal do Estado do Rio de Janeiro , Rio de Janeiro , Brazil.
  • Vieira VLF; v Department of Neurology , Universidade Federal do Espirito Santo , Vitoria , Brazil.
Expert Rev Clin Pharmacol ; 9(4): 541-546, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26794493
ABSTRACT
Natalizumab is a therapeutic option for treating multiple sclerosis (MS) and is particularly efficacious for patients with highly active disease. A long washout period has been recommended between withdrawal of natalizumab and start of fingolimod (another option for treating MS). This long washout period has been associated with a significant increase in MS activity. In the present study, a group of 96 patients who were switched from natalizumab to fingolimod had short washout periods between drugs, or monthly corticosteroid pulse therapy if longer washout periods were recommended. This therapeutic approach led to the lowest reported relapse rate so far, among patients with MS switching from natalizumab to fingolimod (8.3%). No complications from short withdrawal were observed in this group of patients.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Expert Rev Clin Pharmacol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil